Brokerage Firm Rating Update on Amgen (AMGN)

Amgen (AMGN) has an average broker rating of 2.37, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 10 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Amgen (AMGN) : The consensus price target for Amgen (AMGN) is $186.27 for the short term with a standard deviation of $16.14. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $209, however, the pessimist price target for the company is $157.


For the current week, the company shares have a recommendation consensus of Buy. Also, Gabelli & Co. initiates coverage on Amgen (NASDAQ:AMGN). The shares have now been rated Hold by the stock experts at the ratings house. The rating by the firm was issued on August 26, 2016.

Amgen (NASDAQ:AMGN): stock was range-bound between the intraday low of $169.2 and the intraday high of $171.44 after having opened at $169.78 on Wednesdays session. The stock finally closed in the red at $169.78, a loss of -0.12%. The stock remained in the red for the whole trading day. The total traded volume was 2,013,680 shares. The stock failed to cross $171.44 in Wednesdays trading. The stocks closing price on Thursday was $170.84.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.